Wegovy HD: higher dose of semaglutide approved by US agency to treat obesity
The FDA has approved a higher dose of Wegovy (semaglutide) for treating obesity, with Novo Nordisk anticipating similar approval in Brazil.
Ozempic in the SUS and without a patent: how weight-loss pens have already changed the world — and what’s to come
Rio de Janeiro has become the first Brazilian city to offer the medication Ozempic through the Unified Health System (SUS) as part of its initiative in the fight against obesity.
Anvisa analyzes eight medications with semaglutide; see what changes with the patent expiration
Brazil's health regulatory agency Anvisa is currently reviewing eight semaglutide-based drug applications following the recent patent expiration of the popular medications Ozempic and Wegovy.
Ozempic: With the expiration of the patent will prices fall? Will we have a generic version? See what to expect now
The patent on semaglutide, the active ingredient in Ozempic, expires in Brazil, possibly leading to lower prices and generic versions of the drug in the future.
Hypera bets on patent expiration of weight loss pen to boost sales
Hypera's president announced plans for significant sales growth following the expected patent expiration of semaglutide pharmaceuticals.
"Weight Loss Pens": Miracle, Triumph of Science or New Form of Obsession with Slimness?
The article discusses the surge in popularity of GLP-1 analog drugs, particularly semaglutide, as weight loss solutions while addressing the ethical dilemmas and social dynamics surrounding body image.
Why Brazilian 'Ozempic' may take time and patent expiration probably won’t lower prices
The expiration of the semaglutide patent in Brazil will not lead to immediate price reductions for Ozempic due to regulatory and logistical challenges.
17 days before the patent expires, pharmaceutical company lowers the price of Rybelsus and offers free dose of Wegovy
Novo Nordisk has announced a significant price reduction for its medications Rybelsus and Wegovy, ahead of the expiration of the patent for Ozempic.
New oral GLP-1 reduces more glucose and weight than semaglutide in phase 3 study; Orforgliprona increases weight loss by 73%
The experimental drug orforgliprona demonstrated greater glucose control and weight loss compared to oral semaglutide in a phase 3 study for type 2 diabetes treatment.
End of Ozempic patent could reduce price by up to 35%, says laboratory wanting to make generic
The expiration of the semaglutide patent in March is expected to lead to a price reduction of up to 35% for Ozempic, according to pharmaceutical company EMS, which is interested in producing a generic version.
Anvisa is set to decide next week on national versions of Ozempic
Brazil's National Health Surveillance Agency (Anvisa) is expected to announce its decision regarding the registration of national versions of semaglutide-based pens, essential for diabetes treatment, next week.
Mounjaro Rotation' trivializes the use of medications, say specialists
Experts warn that restaurant initiatives offering reduced portions for users of the medication semaglutide, branded as 'Mounjaro Rotation,' may trivialize its use and alter dining dynamics.